Monte Rosa Therapeutics (GLUE)
Develops molecular glue degrader medicines across oncology, immunology, and inflammation.
Something off on this page? Send us feedback.
Builds small-molecule degraders using the QuEEN discovery engine, with clinical programs in oncology, immunology, inflammation, and cardiometabolic disease. The business is pre-commercial, with collaboration revenue from Roche and Novartis rather than approved product sales.
Uses the QuEEN discovery engine to design molecular glue degraders, small-molecule medicines that direct disease-relevant proteins toward cellular degradation. Current named programs include MRT-2359 in oncology, MRT-6160 for immune-mediated disease through Novartis, and MRT-8102 for inflammatory and cardiometabolic settings.
Runs research from Boston and Basel, with a research-heavy workforce and clinical-stage development model. Collaboration agreements with Roche and Novartis provide current revenue while wholly owned and partnered programs advance through trials.
Execution depends on clinical data, regulatory progress, partner activity, and continued financing capacity. No approved product revenue was disclosed in the business materials opened for context.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 7, 2026 | Guggenheim | Reiterate | Rating: —Target: $35 | Target: $28 |
| Aug 3, 2026 | Wedbush | Reiterate | Rating: —Target: $37 | Target: $27 |
| Jul 31, 2026 | Jefferies | Target | Target: $40 | Target: $25 |
| Jul 27, 2026 | Jefferies | Reiterate | Rating: —Target: $31 | Target: $40 |
| Jun 30, 2026 | Guggenheim | Reiterate | Rating: —Target: — | Target: $35 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $621.1M · Total debt $38.0M · Total assets $696.1M · Shareholders' equity $487.3M
- Revenue
- $9.0M
- Operating income
- −$49.1M
- Net income
- −$43.4M
No dividends on record.
| Institutions | ≈ 108.53% | 92.59M shares | |
|---|---|---|---|
| 202 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 8.68% | 7.40M shares | |
| 9 holders · as of Jul 17, 2026 | |||
| Strategic holders | 4.78% | 4.08M shares | |
| 1 holder · as of Oct 30, 2024 | |||
| Adds to | 121.99% | ||
85.31M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 121.99%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Price T Rowe Associates Inc /MD/Institution | 10.39% | 8.86M | as of Jun 30, 2026 |
Nea Management Company, LLCInstitution | 9.02% | 7.69M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.02% | 6.84M | as of Jun 30, 2026 |
Adam GoulburnInsider | 7.64% | 6.51M | filed Apr 22, 2026 |
TCG Crossover Management, LLCInstitution | 5.42% | 4.62M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 16, 2026 | Markus Warmuth | director, officer: President & CEO | −9,500 | $23.18 |
| Jul 15, 2026 | Jennifer Champoux | officer: Chief Operating Officer | −4,351 | $23.38 |
| Jul 6, 2026 | Sharon Townson | officer: Chief Scientific Officer | −6,000 | $23.31 |
| Jun 30, 2026 | Filip Janku | officer: Chief Medical Officer | −5,407 | $24.50 |
| Jun 29, 2026 | Anthony M. Manning | director | −10,000 | $23.11 |
- Kymera Therapeutics
Closest public TPD peer in immunology and molecular glues
- Nurix Therapeutics
TPD platform peer across oncology and autoimmune programs
- C4 Therapeutics
Public TPD specialist with clinical oncology degraders
- Bristol-Myers Squibb
Large pharma leader in CELMoD and TPD medicines
- Novartis (ADR)
Global pharma TPD participant and key immunology partner
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics | $11.97 | −5.04% | $1.06B | — | — | 37.1 | −61.2% |
| Kymera Therapeutics | $115.58 | −5.31% | $10.04B | — | — | 95.6 | +466.4% |
| Nurix Therapeutics | $24.46 | −4.71% | $2.66B | — | — | 72.5 | −79.5% |
| C4 Therapeutics | $3.04 | −8.16% | $366.0M | — | — | 10.4 | +2.8% |
| Bristol-Myers Squibb | $61.74 | −0.82% | $127.16B | 13.7 | 9.7 | 2.6 | +5.7% |
| Novartis (ADR) | $142.20 | +0.65% | $268.53B | 21.3 | 15.1 | 4.8 | +0.9% |
| Median | 17.5 | 12.4 | 10.4 | +2.8% |